1 / 11

Aging and HIV

Aging and HIV. David Alain Wohl , MD Associate Professor of Medicine The University of North Carolina at Chapel Hill. From DA Wohl , MD, at New York, NY: May 03, 2012, IAS-USA. . A 35 yo man, non-IDU, diagnosed with HIV starting HIV therapy at CD4>200 can expect to live into his 70 ’ s.

baakir
Télécharger la présentation

Aging and HIV

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Aging and HIV David Alain Wohl, MDAssociate Professor of MedicineThe University of North Carolina at Chapel Hill From DA Wohl, MD, at New York, NY: May 03, 2012, IAS-USA.

  2. A 35 yo man, non-IDU, diagnosed with HIV starting HIV therapy at CD4>200 can expect to live into his 70’s ART-CC, The Lancet , 2008, 372:293-299

  3. Co-morbidities included: hypertension, diabetes mellitus, hypothyroidism, cardiovascular disease, bone fractures. Poly-pathology is more common in HIV+ patients and increases with age Polypathology (Pp) prevalence among HIV+ cases and HIV-uninfected controls, by age categories. Cases Controls 1% 1% 1% 2% 1% 0.25% 100% 2% 6% 4% 3% 8% 9% 6% 17% 15% 16% 15% 17% 28% 31% 90% 42% 29% 80% 80% 75% 35% 65% 60% 50% 31% 42% 40% 25% 21% 0%  40 yrs  40 yrs 41 to 50 yrs 51 to 60 yrs > 60 yrs 41 to 50 yrs 51 to 60 yrs > 60 yrs n = 542 n = 1,724 n = 452 n = 136 n = 1,626 n = 5,172 n= 1,356 n= 408 Pp prevalence 3.9% 9.0% 20.0% 46.9% 0.5% 1.9% 6.6% 18.7% No age-related diseases 1 co-morbidity 2 co-morbidities 3 co-morbidities 4 co-morbidities Guaraldi G, et al. CID 2011;53:1102-1126.

  4. COHERE Study: Baseline Virologicand Immunologic Profile by Age Baseline CD4 Count Baseline HIV RNA 256 5.1 5.0 5.0 5.0 222 210 4.9 CD4 (cells/mm3) HIV RNA (log10 copies/mL) 4.8 4.8 188 178 178 173 >60 >60 40-49 55-59 40-49 55-59 18-29 30-39 50-54 18-29 30-39 50-54 13-17 13-17 Age at Baseline (years) Age at Baseline (years) COHERE Study Group. AIDS. 2008;22:1463-1113.

  5. COHERE Study:Response by Baseline Age Achieving CD4 Count >200 Cells/mm3 at 12 Months New AIDS Event At 12 Months P<0.0001 for trend P<0.0001 for trend 9.7% 9.6% 9.3% 86.7% 8.5% 85.6% 80.5% 7.0% 76.3% 75.2% Patients (%) Patients (%) 74.7% 73.9% 5.2% 4.8% >60 >60 40-49 55-59 40-49 55-59 18-29 30-39 50-54 18-29 30-39 50-54 13-17 13-17 Age at Baseline (years) Age at Baseline (years) COHERE Study Group. AIDS. 2008;22:1463-1113.

  6. COHERE Study:Continuation of HAART by Baseline Age Discontinuation of All ARTs at 12 Months • Similar rates of discontinuing or switching >1 antiretroviral agent during the first 12 months of HAART • Complete treatment discontinuation was rare • Lower rates were observed among those >40 years of age P<0.0001 for trend 15.3% 14.8% 11.4% Patients (%) 9.2% 7.9% 7.3% 6.9% >60 40-49 55-59 18-29 30-39 50-54 13-17 Age at Baseline (years) COHERE Study Group. AIDS. 2008;22:1463-1113.

  7. Kaiser Permanente Northern California:Immunologic Response and Age • CD4 gains 1 year after HAART initiation were lower in the older group (P=0.046) • 18-39 years of age • +131.8 cells/mm3 • 40-49 years of age • +121.38 cells/mm3 • >50 years of age • +111.8 cells/mm3 • Despite blunted initial immunologic responses in the older group, CD4 counts were similar by year 3 CD4 Cell Count P=0.66 P=0.07 P=0.001 CD4 Count (cells/mm3) Years of Age 18 to 39 (n=2259) 40 to 49 (n=1834) >50 (n=997) 0 1 2 3 4 5 6 Time After HAART Initiation (years) Silverberg MJ, et al. Arch Intern Med. 2007;167:684-691.

  8. DHHS. Available at: http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf.

  9. MACS: Frailty Phenotype in HIV-Positive MSMs 50 to 70 Years of Age Prevalence of Frailty Phenotype • Prospective cohort of MSMs (2009-2010) • 2850 person-visits • HIV positive on HAART (n=1451) • HIV negative (n=92) • Ages 50 to 70 years • Frailty phenotype more common in HIV-positive men versus HIV-negative men • May be effect of HIV infection, HAART, or both • Further longitudinal studies are needed HIV-positive on HAART HIV-negative 33% 24% 20% Prevalence (%) 15% 10% 8% 8% 8% 5% 4% <40 40-49 50-59 60-69 >70 Age Group (years) Desquilbet L, et al. 18th CROI. Boston, 2011. Abstract 794.

More Related